UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy

Oncogene, 2020-11, Vol.39 (48), p.7106-7113

2020

Volltextzugriff (PDF)

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Oncogene, 2022-01, Vol.41 (2), p.191-203

2022

Volltextzugriff (PDF)

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nature (London), 2010-12, Vol.468 (7326), p.973-977

2010

Volltextzugriff (PDF)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Frontiers in immunology, 2019-05, Vol.10, p.990-990

2019

Volltextzugriff (PDF)

regulatory mechanism of Hsp90α secretion and its function in tumor malignancy

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (50), p.21288-21293

2009

Volltextzugriff (PDF)

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Nature biomedical engineering, 2019-04, Vol.3 (4), p.306

2019

Volltextzugriff (PDF)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Nature (London), 2011-12, Vol.480 (7377), p.387-390

2011

Volltextzugriff (PDF)

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

Cancer discovery, 2014-01, Vol.4 (1), p.80-93

2014

Volltextzugriff (PDF)

A novel pan‐cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic

Cancer science, 2019-09, Vol.110 (9), p.2941-2959

2019

Volltextzugriff (PDF)

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Frontiers in oncology, 2020-01, Vol.10, p.48-48

2020

Volltextzugriff (PDF)

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Cancer cell, 2015-02, Vol.27 (2), p.240-256

2015

Volltextzugriff (PDF)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy

Frontiers in pharmacology, 2021-11, Vol.12, p.797852-797852

2021

Volltextzugriff (PDF)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II

Frontiers in pharmacology, 2022-12, Vol.13, p.1106129-1106129

2022

Volltextzugriff (PDF)

MDM4 is a key therapeutic target in cutaneous melanoma

Nature medicine, 2012-08, Vol.18 (8), p.1239-1247

2012

Volltextzugriff (PDF)

Pulmonary Vascular Destabilization in the Premetastatic Phase Facilitates Lung Metastasis

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7529-7537

2009

Volltextzugriff (PDF)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Frontiers in immunology, 2022-10, Vol.13, p.1065937

2022

Volltextzugriff (PDF)

The therapeutic potential and application of marine alkaloids in treating breast cancer

Frontiers in Marine Science, 2024-07, Vol.11

2024

Volltextzugriff (PDF)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

Frontiers in pharmacology, 2019-07, Vol.10, p.726-726

2019

Volltextzugriff (PDF)

Editorial: Public health, public health education, and their future prospects

Frontiers in public health, 2024-04, Vol.12, p.1403535-1403535

2024

Volltextzugriff (PDF)

Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis

Signal transduction and targeted therapy, 2022-02, Vol.7 (1), p.60-60, Article 60

2022

Volltextzugriff (PDF)

Editorial: Linking cellular metabolism to hematological malignancies, volume II

Frontiers in oncology, 2024, Vol.14, p.1387249-1387249

2024

Volltextzugriff (PDF)

Revealing Allosteric Mechanism of Amino Acid Binding Proteins from Open to Closed State

Molecules (Basel, Switzerland), 2023-10, Vol.28 (20), p.7139

2023

Volltextzugriff (PDF)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies

Frontiers in pharmacology, 2020-09, Vol.11, p.591188-591188

2020

Volltextzugriff (PDF)

The biological impact of deuterium and therapeutic potential of deuterium-depleted water

Frontiers in pharmacology, 2024-07, Vol.15, p.1431204

2024

Volltextzugriff (PDF)

Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment

Frontiers in pharmacology, 2024-06, Vol.15, p.1387647

2024

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(69)
Humans
(41)
Oncology
(22)
Biochemistry & Molecular Biology
(21)
Animals
(19)
Cell Line, Tumor
(18)
Cell Biology
(17)
Mice
(17)
Physical Sciences
(15)
Chemistry
(14)
Female
(14)
Melanoma
(12)
Immunotherapy
(11)
Mutation
(11)
Proto-Oncogene Proteins B-Raf - Antagonists & Inhibitors
(11)
Drug Resistance
(10)
Melanoma - Drug Therapy
(10)
Technology
(10)
Tumors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

regulatory mechanism of Hsp90α secretion and its function in tumor malignancy

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

A novel pan‐cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II

MDM4 is a key therapeutic target in cutaneous melanoma

Pulmonary Vascular Destabilization in the Premetastatic Phase Facilitates Lung Metastasis

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

The therapeutic potential and application of marine alkaloids in treating breast cancer

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

Editorial: Public health, public health education, and their future prospects

Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis

Editorial: Linking cellular metabolism to hematological malignancies, volume II

Revealing Allosteric Mechanism of Amino Acid Binding Proteins from Open to Closed State

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies

The biological impact of deuterium and therapeutic potential of deuterium-depleted water

Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment

Suchergebnisse filtern